Therapeutic drug monitoring (TDM) of total valproic acid (TVPA) concentrations is challenging for its variable pharmacokinetics.
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Therapeutic drug monitoring (TDM) of total valproic acid (TVPA) concentrations is challenging for its variable pharmacokinetics.
In our service the TVPA is normalized according to serum albumin (NTVPA).
The accepted serum concentration range is 50-150 mg/L. Higher concentrations could be useful in complicated seizures such as status epilepticus (SE).
The aim of this study was to evaluate the security of high NTVPA levels.
BACKGROUND: MATERIAL AND METHODS:

CONCLUSIONS:
Retrospective observational study in patients treated with VPA included in TDM program with a minimum of two NTVPA levels over 150 mg/L separated by at least 7 days.
NTVPA was calculated from TVPA according to serum albumin*:
1. Expanded therapeutic range NTVPA levels may be a save option to treat complicated seizures such as status epilepticus 2. According to our results, we could propose 245 mg/L as an upper level of therapeutic range of NTVPA with a close monitoring of platelet count and liver enzymes.
 Demographics  24 patients were included (13 men), followed for a mean of 32 days .  Mean age was 62 years .  16 (67 %) patients were admitted to intensive care units.
 Pharmacological treatment  140 TVPA analyses (6 analyses/patient [2-13]).  14 (58 %) were treated for status epilepticus.  The results of the TVPA and NTVPA, albumin serum concentratiorns are shown in Table 1 and Graph 1. 
RESULTS:
Parameters recorded:
 Demographics: age, sex, admission service.
 Pharmacological treatment: VPA indication, dosage, concomitant antiepileptic therapy, serum concentration of TVPA, serum albumin, pharmacological sedation.
 Efficacy variables: seizures, electroencephalogram (EEG).
 Laboratory data: platelet count, liver enzymes (ALT)
 Adverse effects.
NTVPA = (TVPA x unbound fraction)/6,5
Side effects  diarrhea (n=1)  sedation (n=2); however, 15 patients were pharmacologically sedated.
 Laboratory monitoring 116 data of ALT and 119 of platelet count have been analized.  5 patients had ALT levels over two-fold the normal range (> 1,4 ukat/L) at baseline. At the end of the treatment, all of them had values < 1,4 ukat/L. 22 patients had a normal platelet count, and 2 had a platelet count < 135 x10E9/L but stabilize during the treatment. 
